Rules 1.1 Cond 3, 1.7

Appendix 1A

ASX Listing application and agreement

This form is for use by an entity seeking admission to the $^+$ official list as an ASX Listing (for classification as an ASX Debt Listing use Appendix 1B, and for classification as an ASX Foreign Exempt Listing use Appendix 1C). The form is in 3 parts:

Application for admission to the ⁺official list;

Information to be completed; and

3. Agreement to be completed.

1

2.

Information and documents (including this appendix) given to ASX in support of an application become ASX's property and may be made public. This may be prior to admission of the entity and ⁺quotation of its ⁺securities. Publication does not mean that the entity will be admitted or that its ⁺securities will be quoted.

Introduced 1/7/96. Origin: Appendix 1. Amended 1/7/97, 1/7/98, 1/9/99, 13/3/2000, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Part 1 - Application for admission to the official list

Name of entity	ABN
OVOLODILADM LIMITED	74 116 961 250
CYCLOPHARM LIMITED	/4110/01/250

We (the entity) apply for admission to the ⁺official list of Australian Stock Exchange Limited (ASX) and for ⁺quotation of ⁺securities.

Part 2 - Information to be completed

About the entity

You must complete the relevant sections (attach sheets if there is not enough space).

All entities

- 1 Deleted 30/9/2001
- 2 ⁺Main class of ⁺securities
- 3 Additional ⁺classes ⁺securities (except ⁺CDIs)

	Number	+Class	
	135, 712, 616 (see Attachment 23)	ORDINARY FULLY PAID	
of	Number to be quoted	⁺ Class	
	N/A	N/A	

24/10/2005 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

•

		Number not to be quoted	+Class	
		N/A	N/A	
4	Telephone number ¹ , postal address for all correspondence ² , general fax number ³ , fax number for ⁺ company announcements office to confirm release of information to the market ⁴ , and e-mail address for contact purposes ⁵ .	 (03) 9867 2811 Suite 630, Level 6 Queens Road Melbourne VIC 3004 (03) 9820 5957 (General fax number) (03) 9820 5957 (Fax number to confirm Company Announcements) <u>wrichardson@cyclopharm.com.au</u> Attention: Mr W. N. Richardson, Company Secretary 		
5	Address of principal ⁺ security registries for each ⁺ class of ⁺ security (including ⁺ CDIs)	Gould Ralph Pty Ltd Level 42, AAP Centre 259 George Street Sydney NSW 2000 Phone: (02) 9032 3000 Fax: (02) 9032 3088		
6	Annual balance date	31 December		
	anies only entities go to 19)			
7	Name and title of chief executive officer/managing director	Mr John Stewart Sharman (Managing Director)	
8	Name and title of chairperson of directors	Mr Vanda Russell Gould		
9	Names of all directors	Mr Vanda Russell Gould Mr John Stewart Sharman Mr David James Heaney Mr Bernard Claude Salin Mr Henry George Townsing)	

⁺ See chapter 19 for defined terms.

24/10/2005

Appendix 1A Page 2 MEL_Com:34265.1

10	Duration of appointment of directors (if not subject to retirement by rotation) and details of any entitlement to participate in profits	Appointment Date Mr Vanda Russell Gould – 21/11/2005 Mr John Stewart Sharman - 21/11/2005 Mr David James Heaney – 20/11/2006 Mr Bernard Claude Salin – 01/09/2006 Mr Henry George Townsing - 21/11/2005 All but Mr Sharman are subject to Rule 5 of the Constitution (Attachment 5) dealing with rotation. Mr Sharman's appointment is open-ended and his entitlement to participate in profits is permitted by Rule 27.1. The other directors have no such entitlement when acting in their capacity as directors.
11	Name and title of company secretary	Mr William Nicholas Richardson
12	Place of incorporation	Victoria
13	Date of incorporation	31 October 2005
14	Legislation under which incorporated	Corporations Act 2001 (Commonwealth)
15	Address of registered office in Australia	Building 75 Business & Tehnology Park New Illawarra Road Lucas Heights NSW 2234
16	Month in which annual meeting is usually held	Мау
17	Months in which dividends are usually paid (or are intended to be paid)	Annual dividend intended to be paid between April and June. No interim dividend proposed at this stage.
18	If the entity is a foreign company which has a certificated subregister for quoted ⁺ securities, the location of Australian ⁺ security registers	N/A

11/3/2002 MEL_Com:34265.1

9

(

⁺ See chapter 19 for defined terms.

18A	If the entity is a foreign company, the name and address of the entity's Australian agent for service of process	

(Companies now go to 31)

• •

All entities except companies

19	Name and title of chief executive officer/managing director of the responsible entity	N/A
20	Name and title of chairperson of directors of responsible entity	N/A
21	Names of all directors of the responsible entity	N/A
22	Duration of appointment of directors of responsible entity (if not subject to retirement by rotation) and details of any entitlement to participate in profits	N/A
23	Name and title of company secretary of responsible entity	N/A

⁺ See chapter 19 for defined terms.

Appendix 1A Page 4 MEL_Com:34265.1

23A	Trusts only - the names of the members of the compliance committee (if any)	N/A
24	Place of registration of the entity	N/A
25	Date of registration of the entity	N/A
26	Legislation under which the entity is registered	N/A
27	Address of administration office in Australia of the entity	N/A
28	If an annual meeting is held, month in which it is usually held	N/A
29	Months in which distributions are usually paid (or are intended to be paid)	N/A
30	If the entity is a foreign entity which has a certificated subregister for quoted *securities, the location of Australian *security registers	N/A
30A	If the entity is a foreign trust, the name and address of the entity's Australian agent for service of process	N/A

⁺ See chapter 19 for defined terms.

24/10/2005 MEL_Com:34265.1

۲ ۴ ۲۰۰۰ ۲۰۰۰

About the entity

All entities

۲. ۵ ۱۰. ۲. ۵

documents			Where is the information or document to be found? (eg, prospectus cross reference)
31	\square	Evidence of compliance with 20 cent minimum issue price or sale price ¹ , and spread requirements ²	 Prospectus (Attachment 1), page 7, under heading 'Offer and Minimum Subscription' Attachment 26
32		Prospectus, Product Disclosure Statement or information memorandum relevant to the application (250 copies)	Attachment 1 As discussed with Mr Gerraty 10 copies of the version with the printers are attached. Cyclopharm will provide ASX (Ms Kitson) with 40 further copies upon printing being completed on or before 8 December 2006.
33	\square	Cheque for fees	Attachment 24 Initial fees = \$62,154.40 (incl. GST)
34	\boxtimes	Type of subregisters the entity will operate Example: CHESS and certificated subregisters	CHESS and issuer-sponsored sub- registers. See Prospectus (Attachment 1), page 9, under heading 'Chess and Shareholding Statements'
35	\boxtimes	Copies of any contracts referred to in the prospectus, Product Disclosure Statement or information memorandum (including any underwriting agreement)	Attachment 2 (extract from Prospectus) and copies of material contracts provided.
36		A certified copy of any restriction agreement entered into in relation to ⁺ restricted securities	N/A
37		If there are ⁺ restricted securities, undertaking issued by any bank or ⁺ recognised trustee	N/A
38	\boxtimes	(Companies only) - certificate of incorporation or other evidence of status (including any change of name)	Attachment 3
39		(All entities except companies) - certificate of registration or other evidence of status (including change of name)	N/A

Appendix 1A Page 6 MEL_Com:34265.1 24/10/2005

⁺ See chapter 19 for defined terms.

			Where is the information or document to be found? (eg, prospectus cross
			reference)
40	\boxtimes	Copy of the entity's constitution (eg, if a company, the memorandum and articles of	Attachment 5
		association)	
41		Completed checklist that the constitution	Attachment 4
		complies with the listing rules (copy of articles checklist is available from any Companies	
		Department)	
42	\square	A brief history of the entity or, if applicable, the	Prospectus (Attachment 1), page 12, under heading 'Background'
	·	group	under meaning Dackground
42A	\square	Copy of agreement with ASX that documents	Attachment 25
	¥	may be given to ASX and authenticated electronically.	
Abo	ut the	e securities to be quoted	
	ntities	•	
43		Confirmation that the ⁺ securities to be quoted	• The securities are fully paid
10	\bigtriangleup	are eligible to be quoted under the listing rules	ordinary shares;
			• Prospectus (Attachment 1), page 7, under heading 'Terms of the
			Offer'; and
			• Prospectus (Attachment 1), pages 83 and 84, under heading 'Rights
			Attaching to the Shares
44	\square	Voting rights of ⁺ securities to be quoted	• Prospectus (Attachment 1), page
	\leq		83, under heading 'Voting'; andConstitution, Rule 93 (Attachment)
			5), under heading 'Voting at
			Meetings'
45	\square	A specimen certificate/holding statement for	Attachment 6
		each ⁺ class of ⁺ securities to be quoted and a specimen holding statement for ⁺ CDIs	holding statementthere are no CDI's
46	\square	Terms of the *securities to be quoted	• Prospectus (Attachment 1), page 8,
			under heading 'General Terms Applying to New Shares and
			Existing Shares'
			 Constitution (Attachment 5), Rules 110-120 inclusive under heading
			'Shares'
47	\square	A statement setting out the names of the 20	Attachment 7 – This statement will
		largest holders in each ⁺ class of ⁺ securities to be quoted, and the number and percentage of each	alter upon the completion of the IPO share issue and sell down by Vita Life
		*class of *securities held by those holders	Sciences Ltd.

24/10/2005 MEL_Com:34265.1

, í

⁺ See chapter 19 for defined terms.

Appendix 1A ASX Listing application and agreement

• •

48		A distribution schedule of each ⁺ class of ⁺ equity securities to be quoted, setting out the number of holders in the categories - 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over	Attachment 8 – This schedule will alter upon the completion of the IPO share issue and sell down.
49	\square	The number of holders of a parcel of ⁺ securities with a value of more than \$2,000, based on the issue/sale price	Attachment 9 – This attachment will alter upon the completion of the IPO share issue and sell down.
50		Terms of any ⁺ debt securities and ⁺ convertible debt securities	N/A Where is the information or document to be found? (eg, prospectus cross reference)
51		Trust deed for any ⁺ debt securities and ⁺ convertible debt securities	N/A
52		Deleted 24/10/2005.	N/A

All entities with classified assets

(Other entities go to 62)

All ⁺mining exploration entities and, if ASX asks, any other entity that has acquired, or entered into an agreement to acquire a ⁺classified asset, must give ASX the following information.

53	The name of the vendor and details of any relationship of the vendor with us	N/A
54	If the vendor was not the beneficial owner of the ⁺ classified asset at the date of the acquisition or agreement, the name of the beneficial owner(s) and details of the relationship of the beneficial owner(s) to us	N/A
55	The date that the vendor acquired the ⁺ classified asset	N/A
56	The method by which the vendor ⁺ acquired the ⁺ classified asset, including whether by agreement, exercise of option or otherwise	N/A

Appendix 1A Page 8 MEL_Com:34265.1 24/10/2005

⁺ See chapter 19 for defined terms.

57	The consideration passing directly or indirectly from the vendor (when the vendor ⁺ acquired the asset), and whether the consideration has been provided in full	N/A
58	Full details of the ⁺ classified asset, including any title particulars	N/A

24/10/2005 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

ана ала 1946 — Аларана 1946 — Аларана

Where	is	th	e	information	or
docume	nt	to	be	found?	(eg,
prospec	tus	cros	ss r	eference)	

59		The work done by or on behalf of the vendor in developing the ⁺ classified asset. In the case of a ⁺ mining tenement, this includes prospecting in relation to the tenement. If money has been spent by the vendor, state the amount (verification of which may be required by ASX).	N/A
60		The date that the entity ⁺ acquired the ⁺ classified asset from the vendor, the consideration passing directly or indirectly to the vendor, and whether that consideration has been provided in full	N/A
61		A breakdown of the consideration, showing how it was calculated, and whether any experts' reports were commissioned or considered (and if so, with copies attached).	N/A
Abo	ut the	e entity's capital structure	
All e	ntities		
62		Deleted 1/9/99.	
63	\boxtimes	A copy of the register of members, if ASX asks	Attachment 10 – This register will alter upon the completion of the IPO share issue and sell down.
64		A copy of any court orders in relation to a reorganisation of the entity's capital in the last five years	N/A
65	\square	The terms of any ⁺ employee incentive scheme	 Prospectus (Attachment 1), page 84, under heading 'Long Term Incentive Plan' Note that terms are currently being developed
66	\square	The terms of any ⁺ dividend or distribution plan	 Prospectus (Attachment 1), pages 15 and 83, under heading 'Dividends A dividend reinvestment plan is in the process of being developed but a shareholder resolution will be required for it to be adopted.

Appendix 1A Page 10 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

67	The terms of any *securities that will not be quoted	N/A
68	Deleted 1/7/98.	
69	The entity's issued capital (interests), showing separately each ⁺ class of ⁺ security ¹ (except ⁺ CDIs), the amount paid up on each ⁺ class ² , the issue price ³ , the dividend ⁴ (in the case of a trust, distribution) and voting rights attaching to each ⁺ class ⁵ and the conversion terms ⁶ (if applicable)	Attachment 27
70	The number of the entity's debentures, except to bankers, showing the amount outstanding, nominal value and issue price, rate of interest, dates of payment of interest, date and terms of redemption of each ⁺ class and conversion terms (if applicable) Note: This applies whether the securities are quoted or not.	N/A
71	The number of the entity's unsecured notes, showing the amount outstanding, nominal value and issue price, rate of interest, dates of payment of interest, date and terms of redemption of each ⁺ class and conversion terms (if applicable) Note: This applies whether the securities are quoted or not.	N/A
72	The number of the entity's options to ⁺ acquire unissued ⁺ securities, showing the number outstanding Note: This applies whether the securities are quoted or not.	N/A
73	Details of any rights granted to any ⁺ person, or to any class of ⁺ persons, to participate in an issue of the entity's ⁺ securities Note: This applies whether the securities are quoted or not.	N/A
74	If the entity has any *child entities, a list of all *child entities stating in each case the name, the nature of its business and the entity's percentage holding in it. Similar details should be provided for every entity in which the entity holds (directly or indirectly) 20% or more of the issued capital (interests).	Prospectus (Attachment 1), page 53

• • •

⁺ See chapter 19 for defined terms.

^{11/3/2002} MEL_Com:34265.1

About the entity's financial position (Entities meeting the profit test go to 75. For the assets test go to 81A.)

All entities meeting the profit test

75	L

а — і 19. г. – і.

	intitites in		Where is the information or document to be found? (eg, prospectus cross reference)
75		Evidence that the entity has been in the same main business activity for the last 3 full financial years	 2005 Financial Report (Attachment 11), page 6, under heading 'Principal Activities'; 2004 Financial Report (Attachment 11), page 3, under heading 'Principal Activities'; and 2003 Financial Report (Attachment 11), page 3, under heading 'Principal Activities'.
76		Evidence that the entity is a going concern (or successor) and its aggregated profit for the last 3 full financial years	 2005 Financial Report (Attachment 11), page 10, under heading 'Income Statement'; 2004 Financial Report (Attachment 12), page 5, under heading 'Statement of Financial Performance'; and 2003 Financial Report (Attachment 13), page 5, under heading 'Statement of Financial Performance'. Attachment 28
76A		Evidence that the entity's ⁺ profit from continuing operations in the past 12 months exceeded \$400,000	 Prospectus (Attachment 1), page 13, under heading 'Figure 1'; Prospectus (Attachment 1), page 54, under heading 'Consolidated Income Statement'; 2005 Financial Report (Attachment 11), page 10, under heading 'Income Statement'; 30 June 2006 Half Year Financial Report (Attachment 14)
77	\square	Audited ⁺ accounts for the last 3 full financial years and audit reports	 2005 Financial Report (Attachment 11) 2004 Financial Report (Attachment 12) 2003 Financial Report (Attachment 13)
78 - 7	79	Deleted 1/7/97.	
80	\square	Half yearly ⁺ accounts (if required) and audit report or review	30 June 2006 Financial Report (Attachment 14)
80A	\square	Pro forma balance sheet and review	• Prospectus (Attachment 1), page

Appendix 1A Page 12 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

			55, under heading 'Consolidated Balance Sheet';
80B	\square	Statement from all directors or all directors of the responsible entity confirming that the entity is continuing to earn ⁺ profit from continuing operations	Attachment 15
		neeting the assets test one of 81A, 81B or 81C and one of 82 or 83)	
Introdu	ced 1/7/96. A	Amended 1/7/99. Deleted 1/7/97	
81			
81A		For entities other than ⁺ investment entities, evidence of net tangible assets of at least \$2 million or market capitalisation of at least \$10 million	N/A
81B		For ⁺ investment entities other than ⁺ pooled development funds, evidence of net tangible assets of at least \$15 million	N/A
81C		Evidence that the entity is a ⁺ pooled development fund with net tangible assets of at least \$2 million	N/A

11/3/2002 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

· · ·

 $\widehat{}$

		Where is the information or document to be found? (eg, prospectus cross reference)
82	Evidence that at least half of the entity's tota tangible assets (after raising any funds) is no cash or in a form readily convertible to cash (there are no-commitments)	ot
83	Evidence that there are commitments to spend a least half of the entity's cash and assets in form readily convertible to cash (if half or mon of the entity's total tangible assets (after raisin any funds) is cash or in a form readil convertible to cash)	a re ng
84	Statement that there is enough working capita to carry out the entity's stated objectives (an statement by independent expert, if required)	al N/A nd
85	Deleted 1/9/99.	
86	Deleted 1/7/97.	
87	⁺ Accounts for the last 3 full financial years ar audit report, review or statement that ne audited or not reviewed	
87A	Half yearly ⁺ accounts (if required) and aud report, review or statement that not audited on not reviewed	
87B	Audited balance sheet (if required) and aud report	lit N/A
87C	Pro forma balance sheet and review	N/A
(Now go to 100	5)	
88	Deleted 1/7/97.	
89-92C	Deleted 1/9/99.	
93	Deleted 1/7/97.	
94-98C	Deleted 1/9/99.	
99	Deleted 1/7/97.	
100-105C	Deleted 1/9/99.	

Appendix 1A Page 14 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

Informat	lote: Cor ion Mer es to the	npany has treated all references to norandum as though they were Prospectus and has answered the ngly.	Where is the information or document to be found? (eg, prospectus cross reference)
Informati memoran 106	ndum	ntained in the information ails of the entity's existing and proposed activities, level of operations. State the main business	Prospectus (Attachment 1), page 12, under heading "Our Business" and
107	Det	ails of any issues of the entity's ⁺ securities (in all sses) in the last 5 years. Indicate issues for	"Our Opportunity". N/A Attachment 27.
X A	con	sideration other than cash	No shares have been issued for any consideration other than cash.N/A
		memorandum requirements	
All entit		If the entity is a company, a statement that all the information that would be required under section 710 of the Corporations Act if the information memorandum were a prospectus offering for subscription the same number of *securities for which *quotation will be sought is contained in the information memorandum. If the entity is a trust, a statement that all the information that would be required under section 1013C of the Corporations Act if the information memorandum were a Product Disclosure Statement offering for subscription the same number of *securities for which *quotation will be sought is contained in the information memorandum	Attachment 16
109		The signature of every director, and proposed director, of the entity personally or by a ⁺ person authorised in writing by the director (in the case of a trust, director of the responsible entity)	Attachment 15
110	\square	The date the information memorandum is signed	28 November 2006
111(a)		Full particulars of the nature and extent of any interest now, or in the past 2 years, of every director or proposed director of the entity (in the case of a trust, the responsible entity), in the promotion of the entity, or in the property acquired or proposed to be acquired by it	Attachment 17

About the entity's business plan and level of operations

а с ст. ,

⁺ See chapter 19 for defined terms.

^{11/3/2002} MEL_Com:34265.1

.

-

	Informat	ion contained in the information memorandum	Where is the information or document to be found? (eg, prospectus cross reference)
111(b)	\square	If the interest was, or is, as a member or partner in another entity, the nature and extent of the interest of that other entity	Attachment 17
111(c)		If the interest was or is as a member or partner in another entity, a statement of all amounts paid or agreed to be paid to him or her or the entity in cash, *securities or otherwise by any *person to induce him or her to become or to qualify him or her as, a director, or for services rendered by him or her or by the entity in connection with the promotion or formation of the listed entity	Prospectus (Attachment 1), page 89, under heading 'Remuneration by Cyclopharm'.
112(a)	\square	Full particulars of the nature and extent of any interest of every expert in the promotion of the entity, or in the property acquired or proposed to be acquired by it	Prospectus (Attachment 1), page 91, under heading 'Expert's Interests'.
112(b)	\boxtimes	If the interest was or is as a member or partner in another entity, the nature and extent of the interest of that other entity	Prospectus (Attachment 1), page 91, under heading 'Expert's Interests'.
112(c)	\boxtimes	If the interest was or is as a member or partner in another entity, a statement of all amounts paid or agreed to be paid to him or her or the entity in cash, *securities or otherwise by any *person for services rendered by him or her or by the entity in connection with the promotion or formation of the listed entity	Prospectus (Attachment 1), page 91, under heading 'Expert's Interests'.
113	\boxtimes	A statement that ASX does not take any responsibility for the contents of the information memorandum	Attachment 18
114	\square	A statement that the fact that ASX may admit the entity to its ⁺ official list is not to be taken in any way as an indication of the merits of the entity	Attachment 19
115	\square	If the information memorandum includes a statement claiming to be made by an expert or based on a statement made by an expert, a statement that the expert has given, and has not withdrawn, consent to the issue of the information memorandum with the particular statement included in its form and context	1 1

Appendix 1A Page 16 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

116	\square	A statement that the entity has not raised any capital for the 3 months before the date of issue of the information memorandum and will not need to raise any capital for 3 months after the date of issue of the information memorandum	Attachment 21
117		 A statement that a supplementary information memorandum will be issued if the entity becomes ⁺aware of any of the following between the issue of the information memorandum and the date the entity's ⁺securities are ⁺quoted or reinstated. A material statement in the information memorandum is misleading or deceptive. There is a material omission from the information memorandum. There has been a significant change affecting a matter included in the information memorandum. A significant new circumstance has arisen and it would have been required to be included in the information memorandum 	Attachment 22

Information contained in the supplementary information memorandum

118	If there is a supplementary information memorandum:	N/A
	Correction of any deficiency.	
	 Details of any material omission, change or new matter. 	
	• A prominent statement that it is a supplementary information memorandum.	
	• The signature of every director, or proposed director, of the entity personally or by a ⁺ person authorised in writing by the director (in the case of a trust, director of the responsible entity).	
	• The date the supplementary information memorandum is signed.	

Evidence if supplementary information memorandum is issued

119

. . .

Evidence that the supplementary information N/A memorandum accompanied every copy of the information memorandum issued after the date of the supplementary information memorandum.

N/A

11/3/2002 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

Other information

All entities

120

121

122

123

123A

Where is the information or document to be found? (eg, prospectus cross reference)

N/A

Attachment 2

Cyclopharm

Evidence that the supplementary information memorandum was sent to every ⁺person who was sent an information memorandum

> Details of any material contracts entered into between the entity and any of its directors (if a trust, the directors of the responsible entity)

A copy of every disclosure document or Product Disclosure Statement issued, and every information memorandum circulated, in the last 5 years

Information not covered elsewhere and which, in terms of rule 3.1, is likely materially to affect the price or value of the entity's 'securities

The documents which would have been required to be given to ASX under rules 4.1, 4.2, 4.3, 4.5, 5.1, 5.2 and 5.3 had the entity been admitted to the ⁺official list at the date of its application for admission, unless ASX agrees otherwise.

Example: ASX may agree otherwise if the entity was recently incorporated.

Mining exploration entities

A map or maps of the mining tenements prepared by a qualified ⁺person. The maps must indicate the geology and other pertinent features of the tenements, including their extent and location in relation to a capital city or major town, and relative to any nearby properties which have a significant bearing on the potential of the tenements. The maps must be dated and identify the qualified ⁺person and the report to which they relate.

125 Deleted 1/7/97

N/A N/A

N/A – Offers in relation to Cyclopharm

were made by Vita Life Sciences Ltd,

itself

was

only

its then parent company.

incorporated in 2005.

N/A

Appendix 1A Page 18 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

Where is the information or document to be found? (eg, prospectus cross reference)

126	A schedule of ⁺ mining tenements prepared by a qualified person. The schedule must state in relation to each ⁺ mining tenement: the geographical area where the ⁺ mining tenement is situated; the nature of the title to the ⁺ mining tenement; whether the title has been formally confirmed or approved and, if not, whether an application for confirmation or approval is pending and whether the application is subject to challenge; and the ⁺ person in whose name the title to the ⁺ mining tenement is currently held.	N/A
127	If the entity has ⁺ acquired an interest or entered into an agreement to ⁺ acquire an interest in a ⁺ mining tenement from any ⁺ person, a statement detailing the date of the ⁺ acquisition of the interest from the vendor and the purchase price paid and all other consideration (whether legally enforceable or not) passing (directly or indirectly) to the vendor.	N/A
128	A financial statement by the directors (if a trust, the directors of the responsible entity) setting out a program of expenditure together with a timetable for completion of an exploration program in respect of each ⁺ mining tenement or, where appropriate, each group of tenements	N/A
129	A declaration of conformity or otherwise with the Australasian Code for Reporting of Identified Mineral Resources and Ore Reserves for any reports on mineral resources and ⁺ ore reserves	N/A

⁺ See chapter 19 for defined terms.

11/3/2002 MEL_Com:34265.1

• • • •

Part 3 - Agreement

All entities

You must complete this agreement. If you require a seal to be bound, the agreement must be under seal.

We agree:

- 1 Our admission to the 'official list is in ASX's absolute discretion. ASX may admit us on any conditions it decides. 'Quotation of our 'securities is in ASX's absolute discretion. ASX may quote our 'securities on any conditions it decides. Our removal from the 'official list or the suspension or ending of 'quotation of our 'securities is in ASX's absolute discretion. ASX is entitled immediately to suspend 'quotation of our 'securities or remove us from the 'official list if we break this agreement, but the absolute discretion of ASX is not limited.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law, and is not for an illegal purpose.
 - There is no reason why the *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 601MB(1), 737, 738, 992A, 992AA or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from, or connected with, any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Appendix 1A Page 20 MEL_Com:34265.1

⁺ See chapter 19 for defined terms.

- 5 We will comply with the listing rules that are in force from time to time, even if +quotation of our +securities is deferred, suspended or subject to a +trading halt.
- 6 The listing rules are to be interpreted:

•

- in accordance with their spirit, intention and purpose;
- by looking beyond form to substance; and
- in a way that best promotes the principles on which the listing rules are based.
- 7 ASX has discretion to take no action in response to a breach of a listing rule. ASX may also waive a listing rule (except one that specifies that ASX will not waive it) either on our application or of its own accord on any conditions. ASX may at any time vary or revoke a decision on our application or of its own accord.
- 8 A document given to ASX by an entity, or on its behalf, becomes and remains the property of ASX to deal with as it wishes, including copying, storing in a retrieval system, transmitting to the public, and publishing any part of the document and permitting others to do so. The documents include a document given to ASX in support of the listing application or in compliance with the listing rules.
- 9 In any proceedings, a copy or extract of any document or information given to ASX is of equal validity in evidence as the original.
- 10 Except in the case of an entity established in a jurisdiction whose laws have the effect that the entity's *securities cannot be approved under the operating rules of the *approved CS facility:
 - We will satisfy the ⁺technical and performance requirements of the ⁺approved CS facility and meet any other requirements the ⁺approved CS facility imposes in connection with approval of our ⁺securities.
 - When *securities are issued we will enter them in the *approved CS facility's subregister holding of the applicant before they are quoted, if the applicant instructs us on the application form to do so.
 - The ⁺approved CS facility is irrevocably authorised to establish and administer a subregister in respect of the ⁺securities for which ⁺quotation is sought.

⁺ See chapter 19 for defined terms.

^{3/5/2004} MEL_Com:34265.1

- 11 Except in the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility, we confirm that either:

· · · ·

we have given a copy of this application to the $^+$ approved CS facility in accordance with the operating rules of the $^+$ approved CS facility; or

$\overline{\ }$	7
Ϊ	\backslash

we ask ASX to forward a copy of this application to the ⁺approved CS facility.

- 12 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility:
 - The ⁺approved CS facility is irrevocably authorised to establish and administer a subregister in respect of ⁺CDIs.
 - We will make sure that ⁺CDIs are issued over ⁺securities if the holder of quoted ⁺securities asks for ⁺CDIs.
- 13 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility:

- E			
ł			

we have given a copy of this application to the approved CS facility in accordance with the operating rules of the ⁺approved CS facility; or

г	-	
-1		

we ask ASX to forward a copy of this application to the +approved CS facility.

Dated: 30 November 2006

[Proper execution - if the entity has a seal, execution must be under seal]

__ __ __ __ __

Appendix 1A Page 22 MEL_Com:34265.1 3/5/2004

⁺ See chapter 19 for defined terms.

- 11 Except in the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility, we confirm that either:

• • • • • •

we have given a copy of this application to the $^+$ approved CS facility in accordance with the operating rules of the $^+$ approved CS facility; or

\sim	$\overline{\ }$	7
\sim	Ζ	$\overline{\ }$

we ask ASX to forward a copy of this application to the +approved CS facility.

- 12 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility:
 - The ⁺approved CS facility is irrevocably authorised to establish and administer a subregister in respect of ⁺CDIs.
 - We will make sure that ⁺CDIs are issued over ⁺securities if the holder of quoted ⁺securities asks for ⁺CDIs.
- 13 In the case of an entity established in a jurisdiction whose laws have the effect that the entity's 'securities cannot be approved under the operating rules of the 'approved CS facility:

we have given a copy of this application to the approved CS facility in accordance with the operating rules of the ⁺approved CS facility; or

we ask ASX to forward a copy of this application to the ⁺approved CS facility.

Dated: 30 November 2006

The Common Seal of CYCLOPHARM LIMITED was hereunto affixed in the presence of:

Director: Henry Townsing Director: John Sharman

D Sral A.B.N. D 74 116 931 2

NRM

Common

⁺ See chapter 19 for defined terms.

Appendix 1A Page 22

3/5/2004